{"entity":{"id":"bostongene-tumor-portrait","kind":"drug","name":"Tumor Portrait","aka":["BostonGene Tumor Portrait","Tumor Portrait test"],"tldr":"BostonGene's tumour test that adds a reading of the immune cells around the cancer to the usual list of gene changes.","summary":"The Tumor Portrait test from BostonGene identifies biomarkers for response to therapy in advanced solid tumours by combining comprehensive genomic profiling with an analysis of the tumour microenvironment, covering more than 19,000 genes. BostonGene publishes cancer-specific biomarker lists for breast, colorectal, gastric, pancreatic, urinary tract, kidney, prostate, non-small cell lung, head and neck, ovarian, melanoma and sarcoma, and for follicular and diffuse large B-cell lymphoma. Immunohistochemistry for PD-L1 and mismatch repair can be added. The microenvironment types come from BostonGene's transcriptomic classification of more than 10,000 patients into four subtypes conserved across 20 cancers, published in Cancer Cell in 2021. All analyses are run in BostonGene's CAP-accredited, CLIA-certified laboratory.","status":"established","asOf":"2026-11-03","links":[{"label":"BostonGene: Tumor Portrait test","url":"https://bostongene.com/providers/tumor-portrait"},{"label":"Bagaev et al., conserved pan-cancer microenvironment subtypes predict response to immunotherapy (Cancer Cell 2021)","url":"https://doi.org/10.1016/j.ccell.2021.04.014"}],"tags":["test"],"related":["msi-high","tmb-high"],"cancers":["metastatic-cancer"],"sections":[],"technologies":["wes-wgs","cgp","rna-seq"],"targets":[],"drugs":[],"companies":["bostongene"],"institutions":[],"pathways":["tumor-microenvironment"],"terms":["ngs","tmb","msi","immunotherapy-response"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: alongside gene changes linked to approved drugs, the report places the tumour in one of the microenvironment types, which in the published work tracked response to immunotherapy; the type is not by itself a reason to give or withhold a drug."],"brand":"Tumor Portrait","modality":"Tumour profiling test (whole exome and transcriptome with microenvironment classification)","mechanism":"Exome and transcriptome sequencing of the tumour, covering more than 19,000 genes, combined with a classification of the tumour microenvironment from the RNA data.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bostongene-tumor-portrait/","neighbours":{"biomarker":[{"id":"msi-high","kind":"biomarker","name":"MSI-high (microsatellite instability by PCR or sequencing)","route":"/biomarkers/msi-high/"},{"id":"tmb-high","kind":"biomarker","name":"TMB-high (tumour mutational burden >= 10 mutations per megabase)","route":"/biomarkers/tmb-high/"}],"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"bostongene","kind":"company","name":"BostonGene","route":"/companies/bostongene/"}],"pathway":[{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/"}],"term":[{"id":"immunotherapy-response","kind":"term","name":"Immunotherapy response and its prediction","route":"/terms/immunotherapy-response/"},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}]}}